Applications
Lopinavir & Ritonavir Tablets USP (COVID-19) Kinetex 2.6 µm C8 100 x 4.6 mm
25917
Separation Mode: Reversed Phase
Reversed Phase
USP
C8
HPLC
Anti-HIV Agents
Pharmaceutical/Biopharmaceutical
Therapeutic / Clinical
Therapeutic / Clinical

Applications

Lopinavir & Ritonavir Tablets USP (COVID-19) Kinetex 2.6 µm C8 100 x 4.6 mm
Analytes
1
2

Analyte not found

Details
Official Method: USP
LC Conditions (App ID: 25917)
Column:
Brand Name:
Part No:
Elution Type:
Gradient
Mobile Phase:
A: (175:100:100:625) of ACN:MeOH:THF:Buffer (4.1 g/L of monobasic potassium phosphate in water)
Gradient Profile:
Step No.Time(min)%A
10100
250100
Flow Rate:
1.5 mL/min
Temperature:
40°C
System:
Agilent Technologies 1260 Infinity Hybrid SFC/UHPLC Agilent Technologies 1260 Infinity Hybrid SFC/UHPLC
Detection:
LC/UV (DAD, PDA) nm (nanometers) @ 0°C

Order Items Used in This Application

Similar Applications
search
Kinetex 5 µm C8 100 Å, LC Column 150 x 4.6 mm, Ea
Reversed Phase
Luna 3 µm C8(2) 100 Å, LC Column 150 x 4.6 mm, Ea
Reversed Phase
Luna 5 µm C8(2) 100 Å, LC Column 150 x 4.6 mm, Ea
Reversed Phase